Fig. 6.

Late-life IGF-1R modulation improves female lifespan. a Chronic mAb treatment beginning at 78 wks of age (~18 mo) in CB6F1 female mice tended to cause a slight and persistent reduction in body weight (group effect, P = 0.056). b, c This reduction in body weight was attributed to a reduction in lean mass (P = 0.052), rather than adiposity, as assessed by qMR. d Importantly, late-life mAb treatment was able to significantly improve mean (P = 0.023) and median lifespan (P = 0.03), as well as survival after 78 weeks of age (HR = 0.622, P = 0.029; n = 45 per group), but did not improve maximum lifespan. Details regarding these analyses and related R code can be found in the Statistics section and here: [10.17605/OSF.IO/8QGX9. Bars are means ± s.e.m. Dot plots overlaid on bar graphs represent individual data points. NS not significant. *Significantly different from Controls by independent samples t-test, P = 0.052